

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
9 October 2003 (09.10.2003)

PCT

(10) International Publication Number
WO 03/083127 A2

(51) International Patent Classification⁷: **C12Q**

(21) International Application Number: PCT/EP03/03291

(22) International Filing Date: 28 March 2003 (28.03.2003)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
02007267.4 28 March 2002 (28.03.2002) EP

(71) Applicant (for all designated States except US):
DEUTSCHES KREBSFORSCHUNGSZENTRUM
[DE/DE]; Postfach 101949, 69009 Heidelberg (DE).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **BRORS, Benedikt**
[DE/DE]; Im Linsenbühl 42, 69221 Heidelberg (DE).
HAUSER, Nicole [DE/DE]; Ringstr. 31, 69115 Heidelberg (DE).
VINGRON, Martin [DE/DE]; Hueninger Str. 52a, 14195 Berlin (DE).

(74) Agent: **VOSSIUS & PARTNER**; Siebertstrasse 4, 81675 Munich (DE).

(81) Designated States (*national*): AE, AG, AL, AM, AT (utility model), AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ (utility model), CZ, DE (utility model), DE, DK (utility model), DK, DM, DZ, EC, EE (utility model), EE, ES, FI (utility model), FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— without international search report and to be republished upon receipt of that report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: METHOD AND SYSTEM FOR DETERMINING ABSOLUTE MRNA QUANTITIES

(57) Abstract: The present invention is particularly directed to a method and a system for determining absolute mRNA quantities, specifically on cDNA microarrays. The following steps and respective means are provided: providing a microarray; providing at least one or more dilution series of control spots on this microarray; hybridizing with a corresponding control cDNA of known concentration; deriving reference data from the hybridization and using said reference data to calculate absolute mRNA concentrations in one or more samples used.

WO 03/083127 A2

Method and system for determining absolute mRNA quantities

The invention is directed to a method and a system for determining absolute mRNA quantities by means of spotted cDNA microarrays.

The use of DNA microarrays has revolutionized the investigation of gene expression due to its ability to measure mRNA quantities for thousands of different transcripts at the same time¹⁻¹⁶. Briefly, representative single stranded DNA fragments are immobilized on a solid support (e.g. a glass slide) to probe for complementary cDNAs or cRNAs. These are prepared from biological samples as a representation of their mRNA pool. The preparation involves reverse transcription, and – in the case of cRNA – additional in-vitro-transcription as a means for amplification. Complementary DNAs or cRNAs are concomitantly labeled by incorporation of radioactive isotopes or of nucleotides that have been modified by attaching a fluorescent dye. After hybridization to the microarray, weakly or unspecific bound cDNAs or cRNAs are washed away, and the signal is read out by a phosphorimager (for radioactive label) or a confocal laser scanning device (for fluorescent label). Computational image analysis determines for each feature (called “spot”) on the array its position (and thereby its identity) and the signal intensity, which is believed to be linearly related to the original amount of cDNA or cRNA of that species that is represented by this feature.

With DNA microarrays, it has become possible to monitor changes in mRNA levels for thousands of different molecules in a single experiment. The technique of “spotted” cDNA chips has found widespread use, but allows currently to measure only relative changes of mRNA concentration in a cell. Moreover, due to technical limitations in the manufacturing process, results can only be made comparable for chips that stem from the same production series, i.e. experiments are currently limited to approximately 50–200 hybridizations.

There are still a number of technical problems that have to be corrected for in later data analysis. The most prominent problem is normalization, or standardization, which

accounts for differences in labeling efficiency and mRNA amount between two samples whose cDNA representation is hybridized to two different chips, or to the same chip but labeled with fluorescent tags that light up in different colors when excited by UV laser light, and can thus be distinguished¹⁷⁻²⁵.

The object underlying the present invention is to provide an improved method and system for determining absolute mRNA quantities.

This object is achieved with the subject-matter as recited in the claims.

The invention provides a method to overcome these technical limitations and measure absolute mRNA quantities, which are then comparable independent of the chip series used. The method involves a dilution series of control spots on the microarray and hybridization with a corresponding control DNA/cDNA of known concentration. According to a preferred embodiment a model curve is then fitted to the obtained signals for the control, and can be used to calculate absolute mRNA concentrations in the sample used. Since these measurements are done with cDNA microarrays, they are able to incorporate as many as 25,000 different mRNA species in a single hybridization experiment.

Another problem that could not be solved yet is that chips that have been produced by "spotting" display high batch-to-batch variation in the surface concentration of DNA fragments in individual spots. In this method, cDNA templates for the genes that are to be probed for are first amplified by large-scale multiplex polymerase chain reaction (PCR). The amplified fragments are then transferred to the microarray supports (mostly glass chips with chemically modified surfaces) by means of roboting devices, which are able to deliver nanoliter quantities with a spatial precision of better than 100 μm . Recently, ink jet-like printing devices have been used for the same purpose²⁶. In any case, once the produced PCR fragments are exhausted, a new PCR preparation has to be started from the master templates. It is currently impossible to control the yield of the PCR reaction for thousands of different templates at the same time. DNA concentration can be measured thereafter, however, transfer rates and coupling efficiency cannot be captured by this means. Thus, spotting microarrays in different batch results in chips that vary in individual spot DNA concentration by factors of up to 100 compared with a previous

microarray production series. The influence of the DNA spot concentration on recorded signal intensity after hybridization is immediately obvious, and cannot be overcome by competitive hybridization where only a ratio of transcript levels is measured for two samples, one whose cDNA representation serves as internal reference, and one whose mRNA pool is to be investigated. The incomparability has been conclusively demonstrated by Yue and coworkers²⁵, who showed that this ratio is considerably dependent on the DNA spot concentration, and will be the more “compressed” (nearer to 1) the smaller the DNA spot concentration is.

Here, we present a novel method that allows a subsequent computational correction for the influence of the individual DNA spot concentration. It requires dilution series of control DNAs to be present on the array and several hybridizations with a universal target that binds to every spot on the array in defined concentrations. By fitting a model curve to the data obtained from the hybridization with the universal target, a subset of spots can be identified whose corresponding values need correction, whereas for the remaining spots correction would do more harm than benefit. The method extends current microarray applications in two directions. First, it is now possible to measure absolute quantities of different mRNAs by microarrays. Second, and more importantly, it is now possible to compare experiments done on different series of chips, and moreover also between different transcript level measuring systems like cDNA chips, oligonucleotide chips^{10, 11}, SAGE (serial analysis of gene expression)^{27, 28}, and multiplex real-time reverse transcription (RT) PCR^{29, 30}. This extends the “horizon of comparability”, which is currently limited to about 50–200 chips, to the levels that are required for new applications that require investigation of up to 500 samples, e.g. classification of cancer subtypes by means of gene expression profiling.

Throughout this text, the following terms will be used:

- *array, microarray, chip*: a solid support (e.g. chemically modified glass or nylon/polypropylene membrane) that contains a number of features (spots), each containing a single species of DNA fragments
- *feature, spot*: a single location on a microarray where only one species of DNA fragments is bound
- *hybridization*: the process by which two complementary DNA molecules bind to each other, being driven by Watson-Crick base pairing
- *probe*: one of the array-bound DNA fragments that are meant to probe for a specific transcript
- *(solute) target*: the cDNA or cRNA preparation from a biological sample, intended to be the representation of the sample's mRNA pool
- *signal intensity*: the intensity of radioactive radiation or the fluorescence intensity during laser excitation that has been read out for a single spot
- *(biological) sample*: a specimen from the organism under study, derived under defined conditions; e.g., a sample from yeast culture, cell culture, a tumor specimen, a biopsy sample, a blood sample
- *universal target*: a DNA fragment of defined sequence that binds to every spot on an array, e.g. a universal oligonucleotide

The figures relate to preferred embodiments which exemplify the present invention and show the following:

Figure 1: Signal intensities in dependence of DNA spot concentrations and of solute target concentrations for nylon membranes. Data shown are averaged over four independent measurements. Data for 4 representative probe species are shown.

Figure 2: Signal intensities in dependence of DNA spot concentrations and of solute target concentrations for glass slides. Data shown are averaged over four independent measurements. Data for 4 representative probe species are shown.

Figure 3: Data (blue) and fitted model curve (red) for a representative probe fragment on both nylon membrane (a) and a glass slide (b).

Computational Procedures

The values obtained from the hybridization to a universal target, i.e. the read-out signal intensities from the dilution series spots, are taken as a basis for calculating the parameters of a model function by means of non-linear least-squares fitting. As model function, we use the logistic function:

$$\hat{I} = \frac{KI_0 e^{rc_p}}{K + I_0(e^{rc_p} - 1)} \quad (1)$$

where \hat{I} refers to the modeled signal intensity, c_p refers to the probe (or DNA spot) concentration, K represents the asymptotic signal intensity for $c_p \rightarrow \infty$, I_0 is the asymptotic signal intensity for $c_p \rightarrow 0$, and r is a shape parameter. We could demonstrate (see Results) that r does neither depend on the concentration of the solute target cDNA nor on the nature of the probe sequence, and hence should be the same for every spot on the array. Fitting is done by standard gradient optimization procedures for non-linear fitting, we used the Newton-Raphson method as implemented in MATLABTM (MathWorks Inc., Natick, MA, U.S.A.). The confidence of the fitting procedure is greatly enhanced by using several replicates of the dilution series on the chip, we recommend to use at least five.

The model function is used to determine the set of spots whose values need correction for the influence of spot DNA concentration. A critical probe concentration is defined by

$$c_{\text{crit}} = c_p \mid \hat{I} = 0.85K \quad (2)$$

or, analytically

$$c_{crit} = \frac{1}{r} \left[\ln \frac{17(K - I_0)}{3I_0} \right] \quad (3)$$

A hybridization with a universal target will provide for an array of a given series both the possibility to calculate the parameters of the model function, based on the values from the dilution series, and to determine for every spot in the array whether or not its spot DNA concentration is below or above the critical probe concentration. If it is above, no correction is needed since the probe concentration does not influence signal intensity. If it is below, the signal intensity is, in first approximation, linearly dependent on the spot DNA concentration, and values in later hybridizations can be corrected by taking the determined probe concentration from the hybridization with the universal target.

Experiments on nylon and polypropylene membranes

As probe sequences, 16 different PCR fragments from yeast ORFs (Tab. 3) have been spotted in 9 different concentrations (Tab. 1), on both nylon and polypropylene membranes. These arrays have been hybridized with a universal oligonucleotide in 8 different concentrations (Tab. 2). Hybridization experiments have been carried out in quadruplicate, and signal intensities subsequently averaged.

Table 1: spot DNA amounts used

amount of immobilized DNA								
10 amol	50 amol	100 amol	500 amol	1 fmol	5 fmol	10 fmol	25 fmol	50 fmol

Table 2: target concentrations tested

concentration of target (radioactively labeled universal oligonucleotide)							
2 pM	8 pM	20 pM	40 pM	80 pM	120 pM	160 pM	200 pM

Table 3: probe sequences used

ORF identifier	length [bp]
YAR030C	342
YAR043C	350
YCR025C	411
YCL022C	516
YAL055W	543
YAR037W	600
YCL031C	894
YCR034W	1044
YCR045C	1476
YCR024C	1479
YCR048W	1833
YBR280C	1929
YDR422C	2592
YCR030C	2613
YDR430C	2790
YAL035W	3009

As is obvious from Fig. 1, the measured signal intensities depend in a non-linear fashion on both the DNA spot concentration and on the concentration of the solute target. The dependence on DNA spot concentration is best described by a approximately linear interval at low spot concentrations that is followed by a saturation region where no increase in signal intensity can be seen if the spot concentration is increased.

There are no differences in principal shape to the other probe species and to data from polypropylene membranes (data not shown).

Experiments on glass slides Poly-L-lysine-coated glass slides have been used as solid support. The 16 PCR fragments mentioned above (Tab. 3) have been spotted in quadruplicate onto these slides in 8 different concentrations (Tab. 4). The arrays have been hybridized with a fluorescently marked universal oligonucleotide in 5 different concentrations (Tab. 5)

Table 4: amount of spot DNA

amount of immobilized DNA							
0.1 amol	0.5 amol	1 amol	5 amol	10 amol	50 amol	100 amol	300 amol

Table 5: solute target concentrations used

concentration of solute target				
20 pM	200 pM	2 nM	20 nM	200 nM

Data are shown in Fig. 2, and represent averages over the 4 spots on a single slide and the 4 independent replicate hybridizations that have been performed. Apart from a coarser resolution with regard to high DNA spot concentrations and a higher variability of the data, no principal difference is obvious compared to the experiments on nylon or polypropylene membranes.

Fitting of model curve to data Equation (1) has been fitted to the data by means of non-linear optimization. Of main interest is here the estimate for the shape parameter r . This parameter describes the steepness of the curve and hence determines the critical spot concentration which is used to split the range of DNA spot concentrations in a non-influential section at high spot concentrations, and in a range where the signal depends on the spot concentration. The results are shown for representative probe fragments both for nylon membranes and for glass slides (Fig. 3). The model function fits the data well for the transition from influential to non-influential region, while deviating considerably in the region with low spot concentration. However, with regard to the intended purpose, a good fit in this region is not needed.

References

1. Case-Green, S.C., Mir, K.U., Pritchard, C.E. & Southern, E.M. Analysing genetic information with DNA arrays. *Curr. Opin. Chem. Biol.* **2**, 404-410 (1998).
2. DeRisi, J. et al. Use of a cDNA microarray to analyse gene expression patterns in human cancer. *Nat. Genet.* **14**, 457-460 (1996).
3. DeRisi, J.L., Iyer, V.R. & Brown, P.O. Exploring the metabolic and genetic control of gene expression on a genomic scale. *Science* **278**, 680-686 (1997).

4. Duggan, D.J., Bittner, M., Chen, Y., Meltzer, P. & Trent, J.M. Expression profiling using cDNA microarrays. *Nat. Genet.* **21**, 10-14 (1999).
5. Golub, T.R. et al. Molecular classification of cancer: class discovery and class prediction by gene expression monitoring. *Science* **286**, 531-537 (1999).
6. Hegde, P. et al. A concise guide to cDNA microarray analysis. *Biotechniques* **29**, 548-550, 552-554, 556 passim (2000).
7. Hughes, T.R. et al. Functional discovery via a compendium of expression profiles. *Cell* **102**, 109-126 (2000).
8. Iyer, V.R. et al. The transcriptional program in the response of human fibroblasts to serum. *Science* **283**, 83-87 (1999).
9. Khan, J., Bittner, M., Chen, Y., Meltzer, P.S. & Trent, J.M. DNA microarray technology: the anticipated impact on the study of human disease. *Biochim. Biophys. Acta* **1423**, M17-M28 (1999).
10. Lipshutz, R.J., Fodor, S.P., Gingeras, T.R. & Lockhart, D.J. High density synthetic oligonucleotide arrays. *Nat. Genet.* **21**, 20-24 (1999).
11. Lockhart, D.J. et al. Expression monitoring by hybridization to high-density oligonucleotide arrays. *Nat. Biotechnol.* **14**, 1675-1680 (1996).
12. Lockhart, D.J. & Winzeler, E.A. Genomics, gene expression and DNA arrays. *Nature* **405**, 827-836 (2000).
13. Schena, M. Genome analysis with gene expression microarrays. *BioEssays* **18**, 427-431 (1996).
14. Schena, M., Shalon, D., Davis, R.W. & Brown, P.O. Quantitative monitoring of gene expression patterns with a complementary DNA microarray. *Science* **270**, 467-470 (1995).
15. Shalon, D., Smith, S.J. & Brown, P.O. A DNA microarray system for analyzing complex DNA samples using two-color fluorescent probe hybridization. *Genome Res.* **6**, 639-645 (1996).

16. Spellman, P.T. et al. Comprehensive identification of cell cycle-regulated genes of the yeast *Saccharomyces cerevisiae* by microarray hybridization. *Mol. Biol. Cell* 9, 3273-3297 (1998).
17. Beißbarth, T. et al. Processing and quality control of DNA array hybridization data. *Bioinformatics* 16, 1014-1022 (2000).
18. Chudin, E. et al. Assessment of the relationship between signal intensities and transcript concentration for Affymetrix GeneChip(R) arrays. *Genome Biol.* 3, research0005.0001-0005.0010 (2001).
19. Eickhoff, B., Korn, B., Schick, M., Poustka, A. & Bosch, J.v.d. Normalization of array hybridization experiments in differential gene expression analysis. *Nucl. Acids Res.* 27, e33 (1999).
20. Lee, M.-L.T., Kuo, F.C., Whitmore, G.A. & Sklar, J. Importance of replication in microarray gene expression studies: statistical methods and evidence from repetitive cDNA hybridizations. *Proc. Natl. Acad. Sci. U.S.A.* 97, 9834-9839 (2000).
21. Newton, M.A., Kendzierski, C.M., Richmond, C.S., Blattner, F.R. & Tsui, K.W. On differential variability of expression ratios: improving statistical inference about gene expression changes from microarray data. *J. Comput. Biol.* 8, 37-52 (2001).
22. Chen, Y., Dougherty, E.R. & Bittner, M. Ratio-based decisions and the quantitative analysis of cDNA microarray images. *J. Biomed. Opt.* 2, 364-374 (1997).
23. Schadt, E.E., Li, C., Su, C. & Wong, W.H. Analyzing high-density oligonucleotide gene expression array data. *J. Cell. Biochem.* 80, 192-202 (2000).
24. Schuchhardt, J. et al. Normalization strategies for cDNA microarrays. *Nucl. Acids Res.* 28, E47 (2000).
25. Yue, H. et al. An evaluation of the performance of cDNA microarrays for detecting changes in global mRNA expression. *Nucl. Acids Res.* 29, E41 (2001).

26. Hughes, T.R. et al. Expression profiling using microarrays fabricated by an ink-jet oligonucleotide synthesizer. *Nat Biotechnol* **19**, 342-347 (2001).
27. Velculescu, V.E., Zhang, L., Vogelstein, B. & Kinzler, K.W. Serial analysis of gene expression. *Science* **270**, 484-487 (1995).
28. Velculescu, V.E. et al. Analysis of human transcriptomes. *Nat. Genet.* **23**, 387-388 (1999).
29. Bustin, S.A. Absolute quantification of mRNA using real-time reverse transcription polymerase chain reaction assays. *J Mol Endocrinol* **25**, 169-193. (2000).
30. Freeman, W.M., Walker, S.J. & Vrana, K.E. Quantitative RT-PCR: pitfalls and potential. *Biotechniques* **26**, 112-122, 124-115. (1999).

Claims

1. Method for determining absolute mRNA quantities by means of DNA microarrays with the following steps:
 - a. providing a microarray;
 - b. providing at least one or more dilution series of control spots on the microarray;
 - c. hybridizing with a corresponding control DNA of known concentration;
 - d. deriving reference data from the hybridization and
 - e. using said reference data to calculate absolute mRNA concentrations in one or more samples used.
2. Method according to claim 1, further comprising the step of providing a universal tag at each of the immobilized probes on the array to be used for quantification.
3. Method according to claim 1 or 2, wherein a DNA microarray is a cDNA microarray and/or the control DNA is control cDNA.
4. Method according to any of the preceding claims, wherein the reference data comprise a model curve which is fitted or adapted to the obtained signals for control.
5. Method according to any one of the preceding claims, wherein cDNA templates for the genes that are to be probed for are first amplified by large-scale multiplex polymerase chain reaction (PCR) to obtain amplified fragments.
6. Method according to claim 5, wherein said amplified fragments are then transferred to the microarray by means of robotics devices which are able to deliver nanoliter quantities with a spatial precision of better than 100 μm .
7. Method according to any one of the preceding claims, wherein the reference data obtained from the hybridization, e.g., the read-out signal intensities from the dilution

series spots, are taken as a basis for calculating the parameters of a model function by means of non-linear least-squares fitting.

8. Method according to claim 7, wherein for the model function the following function is used:

$$\hat{I} = \frac{KI_0 e^{rc_p}}{K + I_0(e^{rc_p} - 1)}$$

where \hat{I} refers to the modeled signal intensity, c_p refers to the probe (or DNA spot) concentration, K represents the asymptotic signal intensity for $c_p \rightarrow \infty$, I_0 is the asymptotic signal intensity for $c_p \rightarrow 0$, and r is a shape parameter.

9. Method according to any one of claims 4-8, wherein fitting of the reference data is done by gradient optimization procedures.
10. Method according to claim 9, wherein for non-linear fitting, the Newton-Raphson method is used.
11. Method according to any one of the preceding claims, wherein a critical probe function is used to determine the set of spots whose values need correction for the influence of spot DNA concentration, the critical probe concentration function being defined by

$$c_{\text{crit}} = \frac{1}{r} \left[\ln \frac{17(K - I_0)}{3I_0} \right].$$

12. Computer program product comprising program code means stored on a computer readable medium for performing the computable part of the method of at least one of the preceding claims when said program product is run on a computer.
13. System, particularly for performing the method of at least one of claims 1-11, comprising:
 - a. a microarray containing at least one or more dilution series of control spots;
 - b. means for hybridizing with a complementary control DNA of known concentration;
 - c. means for deriving reference data from said hybridization and
 - d. means for making use of said reference data for calculating absolute mRNA concentrations in one or more samples used.
14. System according to claim 13, further comprising means for providing a universal tag at each of the immobilized probes on the array to be used for quantification.
15. Use of a method according to at least one of claims 1-11, a computer program product according to claim 12 and/or a system according to at least one of claims 13 or 14 for determining absolute mRNA quantities on cDNA microarrays.
16. Method of absolute quantification of other biomolecules like DNA or proteins in a complex sample by means of methods according to any one of claims 1-11.




Figure 1: Signal intensities in dependence of DNA spot concentrations and of solute target concentrations for nylon membranes. Data shown are averaged over four independent measurements. Data for 4 representative probe species are shown.




Figure 2: Signal intensities in dependence of DNA spot concentrations and of solute target concentrations for glass slides. Data shown are averaged over four independent measurements. Data for 4 representative probe species are shown.




Figure 3: Data (blue) and fitted model curve (red) for a representative probe fragment on both nylon membrane (a) and a glass slide (b).

SUBSTITUTE SHEET (RULE 26)



(43) International Publication Date
9 October 2003 (09.10.2003)

PCT

(10) International Publication Number
WO 2003/083127 A3

(51) International Patent Classification⁷: **G06F 19/00**

(21) International Application Number:
PCT/EP2003/003291

(22) International Filing Date: 28 March 2003 (28.03.2003)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
02007267.4 28 March 2002 (28.03.2002) EP

(71) Applicant (for all designated States except US):
DEUTSCHES KREBSFORSCHUNGSZENTRUM
[DE/DE]; Postfach 101949, 69009 Heidelberg (DE).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **BRORS, Benedikt**
[DE/DE]; Im Linsenhühl 42, 69221 Heidelberg (DE).
HAUSER, Nicole [DE/DE]; Ringstr. 31, 69115 Heidelberg (DE).
VINGRON, Martin [DE/DE]; Hueninger Str. 52a, 14195 Berlin (DE).

(74) Agent: **VOSSIUS & PARTNER**; Siebertstrasse 4, 81675 Munich (DE).

(81) Designated States (national): AE, AG, AL, AM, AT (utility model), AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ (utility model), CZ, DE (utility model), DE, DK (utility model), DK, DM, DZ, EC, EE (utility model), EE, ES, FI (utility model), FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.


(84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

- with international search report
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments

[Continued on next page]

(54) Title: METHOD AND SYSTEM FOR DETERMINING ABSOLUTE MRNA QUANTITIES



Signal intensities in dependence of DNA spot concentrations and of solute target concentrations for nylon membranes. Data shown are averaged over four independent measurements. Data for 4 representative probe species are shown.

(57) Abstract: The present invention is particularly directed to a method and a system for determining absolute mRNA quantities, specifically on cDNA microarrays. The following steps and respective means are provided: providing a microarray; providing at least one or more dilution series of control spots on this microarray; hybridizing with a corresponding control cDNA of known concentration; deriving reference data from the hybridization and using said reference data to calculate absolute mRNA concentrations in one or more samples used.



(88) Date of publication of the international search report:
29 April 2004

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

INTERNATIONAL SEARCH REPORT

International Application No

PCT/EP 03/03291

A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 G06F19/00

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 G06F

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, WPI Data, BIOSIS

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	<p>SCHUCHHARDT J ET AL: "NORMALIZATION STRATEGIES FOR CDNA MICROARRAYS" NUCLEIC ACIDS RESEARCH, OXFORD UNIVERSITY PRESS, SURREY, GB, vol. 28, no. 10, 15 May 2000 (2000-05-15), pages E47I-E47V, XP000982625 ISSN: 0305-1048 cited in the application abstract; figure 1 page E47II, left-hand column, paragraphs 1-3</p> <p style="text-align: center;">---</p> <p style="text-align: center;">-/--</p>	1-12

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents :

A document defining the general state of the art which is not considered to be of particular relevance

E earlier document but published on or after the international filing date

L document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

O document referring to an oral disclosure, use, exhibition or other means

P document published prior to the international filing date but later than the priority date claimed

T later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

X document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

Y document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

8 document member of the same patent family

Date of the actual completion of the international search

3 March 2004

Date of mailing of the international search report

16/03/2004

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl.
Fax: (+31-70) 340-3016

Authorized officer

Türkeli, Y

INTERNATIONAL SEARCH REPORT

International Application No

PCT/EP 03/03291

A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 G06F19/00

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 G06F

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, WPI Data, BIOSIS

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	<p>SCHUCHHARDT J ET AL: "NORMALIZATION STRATEGIES FOR CDNA MICROARRAYS" NUCLEIC ACIDS RESEARCH, OXFORD UNIVERSITY PRESS, SURREY, GB, vol. 28, no. 10, 15 May 2000 (2000-05-15), pages E47I-E47V, XP000982625 ISSN: 0305-1048 cited in the application abstract; figure 1 page E47II, left-hand column, paragraphs 1-3</p> <p style="text-align: center;">--- -/--</p>	1-12

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents :

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

- *T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- *X* document of particular relevance: the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- *Y* document of particular relevance: the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- *G* document member of the same patent family

Date of the actual completion of the international search

3 March 2004

Date of mailing of the international search report

16/03/2004

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl.
Fax: (+31-70) 340-3016

Authorized officer

Türkeli, Y

INTERNATIONAL SEARCH REPORT

International Application No

PCT/EP 03/03291

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 0135074	A	17-05-2001	US 6471916 B1 29-10-2002
		CA 2390651 A1 17-05-2001	
		EP 1228354 A1 07-08-2002	
		WO 0135074 A1 17-05-2001	

**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record.**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☒ **BLACK BORDERS**
- ☐ **IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**
- ☐ **FADED TEXT OR DRAWING**
- ☐ **BLURRED OR ILLEGIBLE TEXT OR DRAWING**
- ☐ **SKEWED/SLANTED IMAGES**
- ☐ **COLOR OR BLACK AND WHITE PHOTOGRAPHS**
- ☐ **GRAY SCALE DOCUMENTS**
- ☒ **LINES OR MARKS ON ORIGINAL DOCUMENT**
- ☒ **REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**
- ☒ **OTHER:** _____

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.